Coordinatore | KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
Nazionalità Coordinatore | Sweden [SE] |
Totale costo | 16˙155˙448 € |
EC contributo | 11˙994˙553 € |
Programma | FP7-HEALTH
Specific Programme "Cooperation": Health |
Code Call | FP7-HEALTH-2013-INNOVATION-1 |
Funding Scheme | CP-IP |
Anno di inizio | 2013 |
Periodo (anno-mese-giorno) | 2013-10-01 - 2018-09-30 |
# | ||||
---|---|---|---|---|
1 |
KAROLINSKA INSTITUTET
Organization address
address: Nobels Vag 5 contact info |
SE (STOCKHOLM) | coordinator | 4˙027˙080.00 |
2 |
YECURIS CORPORATION FOR PROFIT CORPORATION
Organization address
address: SW SEQUOIA PARKWAY 15055 SUITE 130 contact info |
US (TIGARD OREGON) | participant | 1˙404˙660.00 |
3 |
GATC BIOTECH AG
Organization address
address: JAKOB STADLER PLATZ 7 contact info |
DE (KONSTANZ) | participant | 749˙749.00 |
4 |
GENEDATA AG
Organization address
address: MARGARETHENSTRASSE 38 contact info |
CH (BASEL) | participant | 746˙748.00 |
5 |
NESTLE INSTITUTE OF HEALTH SCIENCES SA
Organization address
address: CAMPUS EPFL QUARTIER DE L INNOVATION BATIMENT G contact info |
CH (LAUSANNE) | participant | 728˙000.00 |
6 |
UNIVERSITY COLLEGE LONDON
Organization address
address: GOWER STREET contact info |
UK (LONDON) | participant | 615˙116.00 |
7 |
CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE
Organization address
address: Rue Michel -Ange 3 contact info |
FR (PARIS) | participant | 574˙500.00 |
8 |
UNIVERSITE PARIS DIDEROT - PARIS 7
Organization address
address: RUE THOMAS MANN 5 contact info |
FR (PARIS) | participant | 523˙000.00 |
9 |
ALMA MATER STUDIORUM-UNIVERSITA DI BOLOGNA
Organization address
address: Via Zamboni 33 contact info |
IT (BOLOGNA) | participant | 514˙000.00 |
10 |
ACADEMISCH ZIEKENHUIS LEIDEN
Organization address
address: Albinusdreef 2 contact info |
NL (LEIDEN) | participant | 412˙750.00 |
11 |
UNIVERSITA DEGLI STUDI DI MILANO
Organization address
address: Via Festa Del Perdono 7 contact info |
IT (MILANO) | participant | 397˙000.00 |
12 | AcureOmics AB | SE | participant | 394˙330.00 |
13 |
ACURE PHARMA AB
Organization address
address: ULLERAKERSVAGEN 38 contact info |
SE (UPPSALA) | participant | 289˙320.00 |
14 |
THE UNIVERSITY OF EDINBURGH
Organization address
address: OLD COLLEGE, SOUTH BRIDGE contact info |
UK (EDINBURGH) | participant | 234˙575.00 |
15 |
PRONEXUS ANALYTICAL AB
Organization address
address: FOGDEVRETEN 2A contact info |
SE (STOCKHOLM) | participant | 200˙565.00 |
16 |
KING'S COLLEGE LONDON
Organization address
address: Strand contact info |
UK (LONDON) | participant | 183˙160.00 |
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
'Recently intense research identified around 4,000 single nucleotide polymorphisms (SNPs) associated with human age related diseases such as metabolic disorders. Despite their highly significant association to pathology, the functional role of these genetic variants is, in most cases, yet to be elucidated. The evolutionary distance of most animal models from humans represents a major limitation for the functional validation of these SNPs. To overcome these difficulties, HUMAN will generate mouse models carrying human hepatocytes or pancreatic βï€cells from either primary cells (hepatocytes) or induced pluripotent stem cells (iPSCs). This innovative approach offers the unique possibility of studying function of genetic risk variants associated with metabolic diseases in an integrated living system (the mouse body), but within human-derived organs, i.e. liver and pancreas. iPSCs used to generate hepatocytes and βï€cells will derive from extreme phenotypes, i.e. patients affected by severe metabolic diseases such as type 2 diabetes (T2D) or subjects selected for exceptional healthy longevity (subjects over 105 years and offspring of nonagenarian sibships) all fully clinically and metabolically characterised and genotyped; they will be selected according to the best combination of risk and protective alleles. We will test the effect of different nutritional regimes (e.g. high fat diet, caloric restriction), to disentangle the complex molecular mechanisms and circuitry across organs (e.g. hypothalamus-liver axis) which lead to pathology. HUMAN associates a core of outstanding basic research institutions to leading European biotech SMEs, and has the capability to produce at least 500 humanised mice. HUMAN will generate iPSCs biobanks and comprehensively manage all associated information. HUMAN is uniquely situated to drive innovation towards a better knowledge of the genetic basis of human metabolic diseases, thereby contributing to healthier aging of European citizens.'
EU-funded researchers are working to unravel the functional role of age-related genes to elucidate ageing.
Development of Group B Streptococcal vaccine to alleviate emerging antibiotic resistance through elimination of current prophylactic antibiotic strategies in GBS prevention
Read More